Download PDF
1
/
Pages
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis
Juan Francisco Navarro-González; Alberto Ortiz; Ana Cebrián Cuenca; Lluís Segú; Belén Pimentel; Unai Aranda; Blanca Lopez-Chicheri; Margarita Capel; Elisenda Pomares Mallol; Christian Caudron; Juan José García Sánchez; Roberto Alcázar Arroyo;
Nefrologia (English Version). 2024;44:857-67
Association of aortic stiffness with abdominal vascular and coronary calcifications in patients with stage 3 and 4 chronic kidney disease
Juan Carlos Hidalgo Santiago; Jary Perelló Martínez; Javier Vargas Romero; José Luis Pallares; Alfredo Michan Doña; Pablo Gómez-Fernández;
Nefrologia (English Version). 2024;44:256-67
Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet
Luciano Artur Lopes Pereira; Catarina Meng; Manuel Augusto Gonçalves Amoedo; Maria Teresa de Sousa Costa Pinto Ferreira Mendes; Marco Alexandre Mateus Prazeres Marques; João Miguel Machado Dória Frazão; André Luiz Loureiro Weigert;
Nefrologia (English Version). 2023;43:197-203